BridgeBio Pharma (BBIO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.42
- Estimate
- -$0.56
- Surprise
- +24.6%
- Revenue (period 2026-09-30)
- $353.2M
- Score at report (before → after)
- 5.9 → 6.0/10
Revenue source: xbrl.
How the report landed
BridgeBio Pharma (BBIO) reported a narrower loss than forecast — adjusted EPS of -$0.42 against the -$0.56 estimate (a 24.6% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.9/10) to Sell at 6.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBIO Sell at 6.1/10.
1 of the last 4 quarters beat the estimate; this quarter's +24.6% surprise compares with a -24.0% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Product: Attruby and Beyonttra
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $78.18
- Price target
- $96.30
- Stop
- $72.71
- Upside to target
- +23.2%
- Reward-to-risk
- 1.6:1
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
BBIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $15.20B
- P/E (fwd)
- -285.4
- 52-week range
- $62.50–$93.42
- Off 52-week high
- 16.3%
- RSI (14)
- 59
- Volume vs avg
- 0.73×
- Score today
- 6.1/10